fashion -WSS

fashion

author：leisure time 2025-08-24 23:26:53 - browse：2392

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Reconstructing family trees of blood cells may help predict disease

Wikipedia

WSS

Venture capital firm's plans to take over Akron hospital face hurdles

Melinda French Gates resigns from Gates Foundation

Syphilis numbers in the United States reach record heights

Cancer researcher Catriona Jamieson is sending tumors into space

Why Medicare shouldn’t cover every FDA

Medicare drug price negotiation legal challenge met with skepticism

knowledge

fashion

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

New clues to why women have higher risk of autoimmune disorders

How one medical school became remarkably diverse

Getting Alzheimer's drug Leqembi to patients can be a challenge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Philips to halt sales of sleep apnea machines in U.S.

In Memoriam: Notable people who died in 2023

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Merck, Johnson & Johnson CEOs will testify on high drug prices

focus

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Philips to halt sales of sleep apnea machines in U.S.

Humana’s losses in Medicare Advantage tank its stock

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Merck, Johnson & Johnson CEOs will testify on high drug prices

knowledge

Wikipedia

Wikipedia

leisure time